Wikipedia
Search Wikipedia:

Latest topics
April 2018
MonTueWedThuFriSatSun
      1
2345678
9101112131415
16171819202122
23242526272829
30      

Calendar Calendar

Free Hit Counter

Epalrestat effects on diabetic neuropathy

Go down

Epalrestat effects on diabetic neuropathy

Post  kokoblue on Tue Apr 27, 2010 1:53 am

Diabetic neuropathy is one of the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief, but they do not affect the underlying pathology nor do they slow progression of the disease.

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process.

Recently, three aldose reductase inhibitors—Epalrestat, fidarestat, and ranirestat— have been evaluated in placebo-controlled clinical trials. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. It is the only drug available in the aldose reductase inhibitor class and was approved in Japan in 1992.

kokoblue

Posts : 15
Join date : 2010-04-21

View user profile

Back to top Go down

Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum